| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA837: Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence |
|
Medicine details |
|
| Medicine name | pembrolizumab (Keytruda®) |
| Formulation | 100 mg/4 ml concentrate for solution for infusion |
| Reference number | 5125 |
| Indication | Adjuvant treatment of adults and adolescents aged 12 years and older with Stage IIB or IIC melanoma who have undergone complete resection |
| Company | Merck Sharp & Dohme Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 16/98/2022 |
| NICE guidance | |
| Commercial arrangement | PAS |